Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2007

GenVec Receives $1.12M to Advance a Gene Therapy for Balance Disorders

  • The National Institute on Deafness and Other Communication Disorders awarded GenVec $1,125,000. The funding will help the company develop a gene-based therapy to treat severe balance disorders.

    Preclinical research reportedly demonstrated that delivery of the human atonal gene utilizing GenVec's adenovector technologies can regenerate lost sensory hair cells and revive inner ear function. The goal of the NIH grant is to translate these research results into an IND application for the treatment of aminoglycoside-induced bilateral vestibular hypofunction (BVH).

    GenVec will receive the grant over five years to support preclinical research in collaboration with Hinrich Staecker, M.D., Ph.D., University of Kansas Medical Center. Research will focus on the advancement of a lead candidate to deliver and express the human atonal gene, generation of materials for preclinical testing, and generation of additional preclinical data to support an IND filing.

    Additionally, work under the grant will explore the use of advanced-generation adenovectors that further enhance delivery, selectivity, and potency of the vector system.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »